Prognostic signature composed of transcription factors accurately predicts the prognosis of gastric cancer patients

Abstract

Background Transcription factors (TFs) are involved in important molecular biological processes of tumor cells and play an essential role in the occurrence and development of gastric cancer (GC). Methods Combined The Cancer Genome Atlas Program and Genotype-Tissue Expression database to extract the expression of TFs in GC, analyzed the differences, and weighted gene co-expression network analysis to extract TFs related to GC. The cohort including the training and validation cohort. Univariate Cox, least absolute contraction and selection operator (LASSO) regression, and multivariate Cox analysis was used for screening hub TFs to construct the prognostic signature in the training cohort. The Kaplan–Meier (K–M) and the receiver operating characteristic curve (ROC) was drawn to evaluate the predictive ability of the prognostic signature. A nomogram combining clinical information and prognostic signatures of TFs was constructed and its prediction accuracy was evaluated through various methods. The target genes of the hub TFs was predicted and enrichment analysis was performed to understand its molecular biological mechanism. Clinical samples and public data of GC was collected to verify its expression and prognosis. 5-Ethynyl-2′-deoxyuridine and Acridine Orange/Ethidium Bromide staining, flow cytometry and Western-Blot detection were used to analyze the effects of hub-TF ELK3 on the proliferation and apoptosis of gastric cancer in vitro. Results A total of 511 misaligned TFs were obtained and 200 GC-related TFs were exposed from them. After systematic analysis, a prognostic signature composed of 4 TFs (ZNF300, ELK3, SP6, MEF2B) were constructed. The KM and ROC curves demonstrated the good predictive ability in training, verification, and complete cohort. The areas under the ROC curve are respectively 0.737, 0.705, 0.700. The calibration chart verified that the predictive ability of the nomogram constructed by combining the prognostic signature of TFs and clinical information was accurate, with a C-index of 0.714. Enriching the target genes of hub TFs showed that it plays an vital role in tumor progression, and its expression and prognostic verification were consistent with the previous analysis. Among them, ELK3 was proved in vitro, and downregulation of its expression inhibited the proliferation of gastric cancer cells, induced proliferation, and exerted anti-tumor effects. Conclusions The 4-TFs prognostic signature accurately predicted the overall survival of GC, and ELK3 may be potential therapeutic targets for GC

ELK3 Controls Gastric Cancer Cell Migration and Invasion by Regulating ECM Remodeling-Related Genes

“…We also analyzed ELK3 mRNA level and protein level with five gastric cancer cell lines ( Figure 1 B,C). From these analyses and a previous report [ 24 ], we selected gastric cancer cell lines exhibiting a relatively low and high expression of the ELK3 gene (SNU484 and SNU638 cells, respectively) and further examined the molecular link between ELK3 and cell migration.…”

Circular RNA hsa_circ_0000144 aggravates ovarian Cancer progression by regulating ELK3 via sponging miR-610

“…In the present study, we found that ELK3 was co-overexpressed with circ_0000144 in ovarian cancer cells. ELK3 has been reported to participate in cancer genesis and development, including gastric [ 29 ], breast [ 17 ], and liver cancers [ 30 ]. Although previous studies have also demonstrated that ELK3 expression is altered in ovarian cancer cell lines and tumors through overexpression of miR-378 [ 19 ], the regulatory mechanism by which ELK3 regulates ovarian cancer remains unclear.…”

Revisiting ameloblastin; addressing the EMT-ECM axis above and beyond oral biology

“…Strikingly, among the putative promoter elements, we mapped transcription factors associated with EMT in physiology and oncogenesis, such as RFX1 (Isaac et al, 2021), BCL6 (Yang et al, 2020), GLI1 (Lei et al, 2022), and OCT1 (Li et al, 2015). Another AMBN promoter analysis (Smith et al, 2020) identified SP6, later suggested to be among the genes implicated in gastric cancer (Zhou et al, 2021) together with MEF2, which resulted from our own AMBN promoter analysis. Our own recent data have associated AMBN expression levels with testicular (Geng et al, 2022) and ovarian cancer (Geng et al, 2023).…”